NR566
OBJECTIVE ASSESSMENT - EXAM
NR 566 / NR566 Final Exam Qs & Ans
(Latest 2026/2027): Advanced Pharmacology
for Care of the Family (Verified Answers) 2026/2027
Advanced Pharmacology for Care of the Family - NR566
50 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
* Pharmacokinetics & Pharmacodynamics * Endocrine & Metabolic Agents
* Drug Interactions & Metabolism * Psychiatric Medication Management
* Cardiovascular Pharmacotherapy * Special Populations & Safety
NR566 - 2026/2027 | Passing Score: 80% | Page 1 of 55 COVER PAGE - 1
, S1 SECTION 1 | Principles of Pharmacology | Q1-Q10 | NR566 2026/2027
Q1 Question 1 of 50
Q1. A 42-year-old patient with chronic hypertension is prescribed a new ACE inhibitor.
The nurse practitioner reviews the drug's pharmacokinetic profile and notes that its
half-life is 8 hours. Based on standard pharmacokinetic principles, approximately how
many hours will it take for the drug to reach steady-state plasma concentration?
A. 8 hours
B. 24 hours
C. 40 hours
D. 56 hours
Correct Answer: C
Rationale:
Steady-state concentration is typically reached after 4 to 5 half-lives. With an 8-hour half-life, 5 half-lives
equal 40 hours. Option A represents only one half-life, which is insufficient. Option B is only 3 half-lives, and
Option D exceeds the standard 5 half-life estimate.
Q2 Question 2 of 50
Q2. A 58-year-old male with type 2 diabetes is started on metformin. The nurse
practitioner explains that the drug primarily works by decreasing hepatic glucose
production and improving peripheral insulin sensitivity. This mechanism of action best
exemplifies which pharmacological concept?
A. Pharmacodynamics
B. Pharmacokinetics
C. Bioavailability
D. First-pass metabolism
Correct Answer: A
Rationale:
Pharmacodynamics describes what the drug does to the body, including mechanisms of action and
physiological effects. Pharmacokinetics (Option B) describes what the body does to the drug. Bioavailability
(Option C) refers to the fraction of drug reaching systemic circulation, and first-pass metabolism (Option D) is
a pharmacokinetic process.
NR566 - 2026/2027 | Passing Score: 80% | Page 2 of 55
, Q3 Question 3 of 50
Q3. A 35-year-old woman is prescribed a prodrug that requires hepatic conversion to its
active metabolite. She has mild hepatic impairment. The nurse practitioner should
anticipate which change in the drug's effect?
A. Increased therapeutic effect due to prolonged half-life
B. Decreased therapeutic effect due to reduced activation
C. No change in therapeutic effect with hepatic impairment
D. Increased toxicity due to accumulation of the prodrug
Correct Answer: B
Rationale:
Prodrugs require metabolic activation, typically in the liver. Hepatic impairment reduces this conversion,
leading to decreased active drug formation and diminished therapeutic effect. Option A is incorrect because
reduced activation does not increase effect. Option D is incorrect because prodrugs are generally inactive
until converted.
Q4 Question 4 of 50
Q4. A 67-year-old patient on multiple medications presents with confusion and
hypotension. The nurse practitioner discovers that drug A displaces drug B from
albumin binding sites. This interaction increases the free fraction of drug B, leading to
enhanced pharmacological effect. This phenomenon is best described as:
A. Pharmacokinetic antagonism
B. Pharmacodynamic synergy
C. Protein binding displacement
D. Enzyme induction
Correct Answer: C
Rationale:
Protein binding displacement occurs when one drug displaces another from plasma protein binding sites,
increasing the free (unbound) fraction and potentially enhancing pharmacological effect. Pharmacokinetic
antagonism (Option A) and pharmacodynamic synergy (Option B) describe different interaction types.
Enzyme induction (Option D) increases metabolism, not free drug concentration.
NR566 - 2026/2027 | Passing Score: 80% | Page 3 of 55
OBJECTIVE ASSESSMENT - EXAM
NR 566 / NR566 Final Exam Qs & Ans
(Latest 2026/2027): Advanced Pharmacology
for Care of the Family (Verified Answers) 2026/2027
Advanced Pharmacology for Care of the Family - NR566
50 100%
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
* Pharmacokinetics & Pharmacodynamics * Endocrine & Metabolic Agents
* Drug Interactions & Metabolism * Psychiatric Medication Management
* Cardiovascular Pharmacotherapy * Special Populations & Safety
NR566 - 2026/2027 | Passing Score: 80% | Page 1 of 55 COVER PAGE - 1
, S1 SECTION 1 | Principles of Pharmacology | Q1-Q10 | NR566 2026/2027
Q1 Question 1 of 50
Q1. A 42-year-old patient with chronic hypertension is prescribed a new ACE inhibitor.
The nurse practitioner reviews the drug's pharmacokinetic profile and notes that its
half-life is 8 hours. Based on standard pharmacokinetic principles, approximately how
many hours will it take for the drug to reach steady-state plasma concentration?
A. 8 hours
B. 24 hours
C. 40 hours
D. 56 hours
Correct Answer: C
Rationale:
Steady-state concentration is typically reached after 4 to 5 half-lives. With an 8-hour half-life, 5 half-lives
equal 40 hours. Option A represents only one half-life, which is insufficient. Option B is only 3 half-lives, and
Option D exceeds the standard 5 half-life estimate.
Q2 Question 2 of 50
Q2. A 58-year-old male with type 2 diabetes is started on metformin. The nurse
practitioner explains that the drug primarily works by decreasing hepatic glucose
production and improving peripheral insulin sensitivity. This mechanism of action best
exemplifies which pharmacological concept?
A. Pharmacodynamics
B. Pharmacokinetics
C. Bioavailability
D. First-pass metabolism
Correct Answer: A
Rationale:
Pharmacodynamics describes what the drug does to the body, including mechanisms of action and
physiological effects. Pharmacokinetics (Option B) describes what the body does to the drug. Bioavailability
(Option C) refers to the fraction of drug reaching systemic circulation, and first-pass metabolism (Option D) is
a pharmacokinetic process.
NR566 - 2026/2027 | Passing Score: 80% | Page 2 of 55
, Q3 Question 3 of 50
Q3. A 35-year-old woman is prescribed a prodrug that requires hepatic conversion to its
active metabolite. She has mild hepatic impairment. The nurse practitioner should
anticipate which change in the drug's effect?
A. Increased therapeutic effect due to prolonged half-life
B. Decreased therapeutic effect due to reduced activation
C. No change in therapeutic effect with hepatic impairment
D. Increased toxicity due to accumulation of the prodrug
Correct Answer: B
Rationale:
Prodrugs require metabolic activation, typically in the liver. Hepatic impairment reduces this conversion,
leading to decreased active drug formation and diminished therapeutic effect. Option A is incorrect because
reduced activation does not increase effect. Option D is incorrect because prodrugs are generally inactive
until converted.
Q4 Question 4 of 50
Q4. A 67-year-old patient on multiple medications presents with confusion and
hypotension. The nurse practitioner discovers that drug A displaces drug B from
albumin binding sites. This interaction increases the free fraction of drug B, leading to
enhanced pharmacological effect. This phenomenon is best described as:
A. Pharmacokinetic antagonism
B. Pharmacodynamic synergy
C. Protein binding displacement
D. Enzyme induction
Correct Answer: C
Rationale:
Protein binding displacement occurs when one drug displaces another from plasma protein binding sites,
increasing the free (unbound) fraction and potentially enhancing pharmacological effect. Pharmacokinetic
antagonism (Option A) and pharmacodynamic synergy (Option B) describe different interaction types.
Enzyme induction (Option D) increases metabolism, not free drug concentration.
NR566 - 2026/2027 | Passing Score: 80% | Page 3 of 55
